The current state of preclinical prostate cancer animal models

Kenneth J. Pienta, Cory Abate-Shen, David B. Agus, Ricardo M. Attar, Leland W.K. Chung, Norman M. Greenberg, William C. Hahn, John T. Isaacs, Nora M. Navone, Donna M. Peehl, Jonathon W. Simons, David B. Solit, Howard R. Soule, Terry A. VanDyke, Michael J. Weber, Lily Wu, Robert L. Vessella

Research output: Contribution to journalReview article

88 Citations (Scopus)

Abstract

Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field of prostate cancer research continues to be hindered by the lack of relevant preclinical models to study tumorigenesis and to further development of effective prevention and therapeutic strategies. The Prostate Cancer Foundation held a Prostate Cancer Models Working Group (PCMWG) Summit on August 6th and 7th, 2007 to address these issues. The PCMWG reviewed the state of prostate cancer preclinical models and identified the current limitations of cell line, xenograft and genetically engineered mouse models that have hampered the transition of scientific findings from these models to human clinical trials. In addition the PCMWG identified administrative issues that inhibit the exchange of models and impede greater interactions between academic centers and these centers with industry. The PCMWG identified potential solutions for discovery bottlenecks that include: (1) insufficient number of models with insufficient molecular and biologic diversity to reflect human cancer, (2) a lack of understanding of the molecular events that define tumorigenesis, (3) a lack of tools for studying tumor-host interactions, (4) difficulty in accessing model systems across institutions, and (5) addressing why preclinical studies appear not to be predictive of human clinical trials. It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions.

Original languageEnglish (US)
Pages (from-to)629-639
Number of pages11
JournalProstate
Volume68
Issue number6
DOIs
StatePublished - May 1 2008

Fingerprint

Prostatic Neoplasms
Animal Models
Carcinogenesis
Clinical Trials
Cell Line
Heterografts
Epigenomics
Neoplasms
Industry
Morbidity
Mortality
Research

Keywords

  • Cell lines
  • Genetically engineered
  • Mouse

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Pienta, K. J., Abate-Shen, C., Agus, D. B., Attar, R. M., Chung, L. W. K., Greenberg, N. M., ... Vessella, R. L. (2008). The current state of preclinical prostate cancer animal models. Prostate, 68(6), 629-639. https://doi.org/10.1002/pros.20726

The current state of preclinical prostate cancer animal models. / Pienta, Kenneth J.; Abate-Shen, Cory; Agus, David B.; Attar, Ricardo M.; Chung, Leland W.K.; Greenberg, Norman M.; Hahn, William C.; Isaacs, John T.; Navone, Nora M.; Peehl, Donna M.; Simons, Jonathon W.; Solit, David B.; Soule, Howard R.; VanDyke, Terry A.; Weber, Michael J.; Wu, Lily; Vessella, Robert L.

In: Prostate, Vol. 68, No. 6, 01.05.2008, p. 629-639.

Research output: Contribution to journalReview article

Pienta, KJ, Abate-Shen, C, Agus, DB, Attar, RM, Chung, LWK, Greenberg, NM, Hahn, WC, Isaacs, JT, Navone, NM, Peehl, DM, Simons, JW, Solit, DB, Soule, HR, VanDyke, TA, Weber, MJ, Wu, L & Vessella, RL 2008, 'The current state of preclinical prostate cancer animal models', Prostate, vol. 68, no. 6, pp. 629-639. https://doi.org/10.1002/pros.20726
Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LWK, Greenberg NM et al. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 1;68(6):629-639. https://doi.org/10.1002/pros.20726
Pienta, Kenneth J. ; Abate-Shen, Cory ; Agus, David B. ; Attar, Ricardo M. ; Chung, Leland W.K. ; Greenberg, Norman M. ; Hahn, William C. ; Isaacs, John T. ; Navone, Nora M. ; Peehl, Donna M. ; Simons, Jonathon W. ; Solit, David B. ; Soule, Howard R. ; VanDyke, Terry A. ; Weber, Michael J. ; Wu, Lily ; Vessella, Robert L. / The current state of preclinical prostate cancer animal models. In: Prostate. 2008 ; Vol. 68, No. 6. pp. 629-639.
@article{410542ff5299484f9ac9c5d8e21fc3fd,
title = "The current state of preclinical prostate cancer animal models",
abstract = "Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field of prostate cancer research continues to be hindered by the lack of relevant preclinical models to study tumorigenesis and to further development of effective prevention and therapeutic strategies. The Prostate Cancer Foundation held a Prostate Cancer Models Working Group (PCMWG) Summit on August 6th and 7th, 2007 to address these issues. The PCMWG reviewed the state of prostate cancer preclinical models and identified the current limitations of cell line, xenograft and genetically engineered mouse models that have hampered the transition of scientific findings from these models to human clinical trials. In addition the PCMWG identified administrative issues that inhibit the exchange of models and impede greater interactions between academic centers and these centers with industry. The PCMWG identified potential solutions for discovery bottlenecks that include: (1) insufficient number of models with insufficient molecular and biologic diversity to reflect human cancer, (2) a lack of understanding of the molecular events that define tumorigenesis, (3) a lack of tools for studying tumor-host interactions, (4) difficulty in accessing model systems across institutions, and (5) addressing why preclinical studies appear not to be predictive of human clinical trials. It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions.",
keywords = "Cell lines, Genetically engineered, Mouse",
author = "Pienta, {Kenneth J.} and Cory Abate-Shen and Agus, {David B.} and Attar, {Ricardo M.} and Chung, {Leland W.K.} and Greenberg, {Norman M.} and Hahn, {William C.} and Isaacs, {John T.} and Navone, {Nora M.} and Peehl, {Donna M.} and Simons, {Jonathon W.} and Solit, {David B.} and Soule, {Howard R.} and VanDyke, {Terry A.} and Weber, {Michael J.} and Lily Wu and Vessella, {Robert L.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1002/pros.20726",
language = "English (US)",
volume = "68",
pages = "629--639",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - The current state of preclinical prostate cancer animal models

AU - Pienta, Kenneth J.

AU - Abate-Shen, Cory

AU - Agus, David B.

AU - Attar, Ricardo M.

AU - Chung, Leland W.K.

AU - Greenberg, Norman M.

AU - Hahn, William C.

AU - Isaacs, John T.

AU - Navone, Nora M.

AU - Peehl, Donna M.

AU - Simons, Jonathon W.

AU - Solit, David B.

AU - Soule, Howard R.

AU - VanDyke, Terry A.

AU - Weber, Michael J.

AU - Wu, Lily

AU - Vessella, Robert L.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field of prostate cancer research continues to be hindered by the lack of relevant preclinical models to study tumorigenesis and to further development of effective prevention and therapeutic strategies. The Prostate Cancer Foundation held a Prostate Cancer Models Working Group (PCMWG) Summit on August 6th and 7th, 2007 to address these issues. The PCMWG reviewed the state of prostate cancer preclinical models and identified the current limitations of cell line, xenograft and genetically engineered mouse models that have hampered the transition of scientific findings from these models to human clinical trials. In addition the PCMWG identified administrative issues that inhibit the exchange of models and impede greater interactions between academic centers and these centers with industry. The PCMWG identified potential solutions for discovery bottlenecks that include: (1) insufficient number of models with insufficient molecular and biologic diversity to reflect human cancer, (2) a lack of understanding of the molecular events that define tumorigenesis, (3) a lack of tools for studying tumor-host interactions, (4) difficulty in accessing model systems across institutions, and (5) addressing why preclinical studies appear not to be predictive of human clinical trials. It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions.

AB - Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field of prostate cancer research continues to be hindered by the lack of relevant preclinical models to study tumorigenesis and to further development of effective prevention and therapeutic strategies. The Prostate Cancer Foundation held a Prostate Cancer Models Working Group (PCMWG) Summit on August 6th and 7th, 2007 to address these issues. The PCMWG reviewed the state of prostate cancer preclinical models and identified the current limitations of cell line, xenograft and genetically engineered mouse models that have hampered the transition of scientific findings from these models to human clinical trials. In addition the PCMWG identified administrative issues that inhibit the exchange of models and impede greater interactions between academic centers and these centers with industry. The PCMWG identified potential solutions for discovery bottlenecks that include: (1) insufficient number of models with insufficient molecular and biologic diversity to reflect human cancer, (2) a lack of understanding of the molecular events that define tumorigenesis, (3) a lack of tools for studying tumor-host interactions, (4) difficulty in accessing model systems across institutions, and (5) addressing why preclinical studies appear not to be predictive of human clinical trials. It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions.

KW - Cell lines

KW - Genetically engineered

KW - Mouse

UR - http://www.scopus.com/inward/record.url?scp=42949126281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949126281&partnerID=8YFLogxK

U2 - 10.1002/pros.20726

DO - 10.1002/pros.20726

M3 - Review article

C2 - 18213636

AN - SCOPUS:42949126281

VL - 68

SP - 629

EP - 639

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 6

ER -